Advertisement
Advertisement
http://www.eahad2015.com

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Treatment with Interferon plus Ribavirin in anti-HIV Negative Patients with Congenital Coagulation Disorders and Chronic Hepatitis C

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2000: 83/6 (June) pp.802-970
Pages: 807-810

Treatment with Interferon plus Ribavirin in anti-HIV Negative Patients with Congenital Coagulation Disorders and Chronic Hepatitis C

Silvia Sauleda (1) , Juan Ignacio Esteban (2) , Carmen Altisent (3) , Lluís Puig (1) , Rafael Esteban (2) , Jaume Guardia (2)
From the (1) Centre de Transfusió i Banc de Teixits, Servei Català de la Salut, (2) Liver Unit, (3) Hemofilia Unit, Hospital General Universitari Vall d’Hebron, Barcelona, Spain

Summary

Background. Hepatitis C virus (HCV) infected hemophiliacs respond at low rate to interferon (IFN) monotherapy. Aims. To assess efficacy of IFN and RBV in HIV negative hemophiliacs with chronic hepatitis C and identify early predictive factors of response. Methods. Twenty naive patients were treated with interferon and RBV for twelve months. Response was assessed by both serial ALT and HCV RNA levels. Results. Normalization of ALT with clearance of HCV RNA occurred in seven (35%) patients. Age and age at infection were the only features associated with a higher likelihood of response. In all responders the viral load had decreased by at least one log within two months of starting treatment. Conclusions. Combination of interferon and ribavirin is well tolerated by hemophiliacs who achieve similar sustained response rates to non-hemophiliacs. Quantitative assessment of viral load at two months of treatment is a useful method to identify non-responders at an early stage.